Ovid Stock Based Compensation To Revenue from 2010 to 2024
| OVID Stock | USD 1.06 0.01 0.95% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 18.59914474 | Current Value 19.53 | Quarterly Volatility 6.49025346 |
Check Ovid Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ovid Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 3.3 M, Selling General Administrative of 22.5 M or Total Revenue of 372.1 K, as well as many indicators such as Price To Sales Ratio of 609, Dividend Yield of 0.0 or PTB Ratio of 3.82. Ovid financial statements analysis is a perfect complement when working with Ovid Therapeutics Valuation or Volatility modules.
Ovid | Stock Based Compensation To Revenue |
Latest Ovid Therapeutics' Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Ovid Therapeutics over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Ovid Therapeutics' Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ovid Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Ovid Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 3.27 | |
| Geometric Mean | 0.87 | |
| Coefficient Of Variation | 198.37 | |
| Mean Deviation | 4.36 | |
| Median | 0.60 | |
| Standard Deviation | 6.49 | |
| Sample Variance | 42.12 | |
| Range | 19.5057 | |
| R-Value | 0.63 | |
| Mean Square Error | 27.20 | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | 0.92 | |
| Total Sum of Squares | 589.73 |
Ovid Stock Based Compensation To Revenue History
About Ovid Therapeutics Financial Statements
Ovid Therapeutics stakeholders use historical fundamental indicators, such as Ovid Therapeutics' Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Although Ovid Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ovid Therapeutics' assets and liabilities are reflected in the revenues and expenses on Ovid Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ovid Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 18.60 | 19.53 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ovid Therapeutics is a strong investment it is important to analyze Ovid Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ovid Therapeutics' future performance. For an informed investment choice regarding Ovid Stock, refer to the following important reports:Check out the analysis of Ovid Therapeutics Correlation against competitors. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share 0.009 | Quarterly Revenue Growth 0.587 | Return On Assets (0.36) | Return On Equity (0.37) |
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.